Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.

NCT06133088 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

53

Enrollment

OTHER

Sponsor class

Conditions

Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed

Interventions

DRUG: dalpiciclib; fluvestrant; compound gossypol acetate tablets

Sponsor

Zhejiang Cancer Hospital